MDM2 and hematopoietic and lymphoid cell neoplasm: After the identification of compounds that modulate the p53 pathways, which arrest cell growth and induce apoptosis, multiple inhibitors of the p53–MDM2 interaction have been suggested as potential treatments for solid tumors, hematological cancers, and ocular diseases [12,13].